Zurezko aterpe baten era biltegi baten diseinua eta kalkulua

Barakaldo herrian dagoen Arteagabeitia eskolako jolastokia estaltzeko zurezko aterpe baten diseinua eta kalkulua. Honetaz aparte, lau isurkiko zurezko biltegi bat ere diseinatu eta kalkulatuko da

Thermal Design and Performance of the Electrical Distribution Feed Box of the LHC prototype cell

The Electrical Distribution Feed Box (DFBS) is a 4.5 K saturated liquid helium cryostat constructed for the Large Hadron Collider (LHC) Prototype Cell (String 2). The thermal design of the DFBS is presented, with emphasis on the modelling of the cooling of the current lead chimneys via the helium bath boil-off gas and on the design of the lambda plate. The expected performance is compared to measurements done during the first operation phase of the LHC prototype cell

The Cryogenic System for the LHC Test String 2: Design, Commissioning and Operation

A 107-m long superconducting magnet string representing a full-cell of the LHC machine was designed for assembly and commissioning at CERN in order to validate the final design choices. This new facility, thereafter called Test String 2, and its cryogenic infrastructure cons ist of feed and return boxes coupled via transfer lines to a 6 kW @ 4.5 K refrigerator and to a low pressure pumping group, a separate cryogenic distribution line, an electrical feed box with HTS current leads, 2 quadrupole and 6 dipole prototype and pre-series superconducting magnets

Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)

Objective: We assessed trabectedin in patients with advanced uterine leiomyosarcoma (uLMS) in real-life clinical practice given according to the marketing authorization. Methods: Thirty-six women from 11 tertiary hospitals across Spain who received trabectedin after anthracycline-containing regimen/s were retrospectively analyzed. The primary endpoint was progression-free survival (PFS). Results: Median PFS and overall survival (OS) since starting trabectedin treatment were 5.4 (95%CI: 3.5–7.3) and 18.5 months (95%CI: 11.5–25.6), respectively. Median OS was significantly higher (P = 0.028) in patients receiving trabectedin in = 2nd line (25.3 months) than in = 3rd (15.1 months) and with ECOG performance status = 1 at trabectedin start (19.8 months) than ECOG 2–3 (6.0 months, P = 0.013). When calculating OS since diagnosis, patients had longer OS with localized disease at diagnosis (87.4 months) vs. locally advanced (30.0 months) or metastatic (44.0 months, P = 0.041); and patients who received adjuvant therapy (87.4 months) compared with those who did not (30.0 months, P = 0.003), especially when receiving radiochemotherapy (106.7 months, P = 0.027). One patient (2.8%) had a complete response (CR) and nine patients (25.0%) achieved a partial response (PR) for an objective response rate of 27.8% with median response duration of 11 months (range: 4–93). Eighteen patients (50.0%) had disease stabilization for a disease control rate (DCR) of 77.8%. More patients receiving trabectedin in 1st-line of advanced disease achieved CR (16.7%) and PR (50.0%) than those in = 2nd line/s (0.0% and 20.0%), whereas the DCR was similar across treatment lines. Reversible neutropenia was the most common grade 3/4 laboratory abnormality (19.4%). Conclusions: Trabectedin confers clinical benefit in patients with recurrent/metastatic uLMS, given after failure to an anthracycline-based regimen being comparable to those reported in clinical trials and with a manageable safety profile

SUB-OCEAN: subsea dissolved methane measurements using an embedded laser spectrometer technology

This document is the Accepted Manuscript version of a Published Work that appeared in final form in Environmental Science and Technology, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://doi.org/10.1021/acs.est.7b06171.We present a novel instrument, the Sub-Ocean probe, allowing in situ and continuous measurements of dissolved methane in seawater. It relies on an optical feedback cavity enhanced absorption technique designed for trace gas measurements and coupled to a patent-pending sample extraction method. The considerable advantage of the instrument compared with existing ones lies in its fast response time of the order of 30 s, that makes this probe ideal for fast and continuous 3D-mapping of dissolved methane in water. It could work up to 40 MPa of external pressure and it provides a large dynamic range, from subnmol of CH4 per liter of seawater to mmol L-1. In this work, we present laboratory calibration of the instrument, intercomparison with standard method and field results on methane detection. The good agreement with the headspace equilibration technique followed by gas-chromatography analysis supports the utility and accuracy of the instrument. A continuous 620-m depth vertical profile in the Mediterranean Sea was obtained within only 10 min and it indicates background dissolved CH4 values between 1 and 2 nmol L-1 below the pycnocline, similar to previous observations conducted in different ocean settings. It also reveals a methane maximum at around 6 m of depth that may reflect local production from bacterial transformation of dissolved organic matter

The deep-sea hub of the ANTARES neutrino telescope

The ANTARES neutrino telescope, currently under construction at 2500 m depth off the French Mediterranean coast, will contain 12 detection lines, powered and read out through a deep-sea junction box (JB) hub. Electrical energy from the shore station is distributed through a transformer with multiple secondary windings and a plugboard with 16 deep sea-mateable electro-optic connectors. Connections are made to the JB outputs using manned or remotely operated submersible vehicles. The triply redundant power management and slow control system is based on two identical AC-powered systems, communicating with the shore through 160 Mb/s fibre G-links and a third battery-powered system using a slower link. We describe the power and slow control systems of the underwater hub

Streptococcus-associated vasculitis: a role for antibiotic therapy?

Numerous post-Streptococcal syndromes (PSS) have been described in the literature. The role of antibiotic therapy in the management of PSS is best established with acute rheumatic fever. We present a patient with streptococcus-associated medium vessel vasculitis with multiple flares despite immunosuppressive therapy that achieved a sustained remission with long term oral penicillin V 250 mg twice daily

Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer

Venous thromboembolism (VTE) is a leading cause of death among patients with cancer. Outpatients with cancer should be periodically assessed for VTE risk, for which the Khorana score is commonly recommended. However, it has been questioned whether this tool is sufficiently accurate at identifying patients who should receive thromboprophylaxis. The present work proposes a new index, TiC-Onco risk score to be calculated at the time of diagnosis of cancer, that examines patients' clinical and genetic risk factors for thrombosis. We included 391 outpatients with a recent diagnosis of cancer and candidates for systemic outpatient chemotherapy. All were treated according to standard guidelines. The study population was monitored for 6 months, and VTEs were recorded. The Khorana and the TiC-Onco scores were calculated for each patient and their VTE predictive accuracy VTEs was compared. We recorded 71 VTEs. The TiC-Onco risk score was significantly better at predicting VTE than the Khorana score (AUC 0.73 vs. 0.58, sensitivity 49 vs. 22%, specificity 81 vs. 82%, PPV 37 vs. 22%, and NPV 88 vs. 82%). TiC-Onco risk score performed significantly better than Khorana score at identifying cancer patients at high risk of VTE who would benefit from personalised thromboprophylaxis

Efficacy and safety of trabectedin in metastatic uterine leiomyosarcoma: A retrospective multicenter study of the Spanish ovarian cancer research group (GEICO)

Objective: We assessed trabectedin in patients with advanced uterine leiomyosarcoma (uLMS) in real-life clinical practice given according to the marketing authorization. Methods: Thirty-six women from 11 tertiary hospitals across Spain who received trabectedin after anthracyclinecontaining regimen/s were retrospectively analyzed. The primary endpoint was progression-free survival (PFS). Results: Median PFS and overall survival (OS) since starting trabectedin treatment were 5.4 (95%CI: 3.5–7.3) and 18.5 months (95%CI: 11.5–25.6), respectively. Median OS was significantly higher (P = 0.028) in patients receiving trabectedin in ≤ 2nd line (25.3 months) than in ≥ 3rd (15.1 months) and with ECOG performance status ≤ 1 at trabectedin start (19.8 months) than ECOG 2–3 (6.0 months, P = 0.013). When calculating OS since diagnosis, patients had longer OS with localized disease at diagnosis (87.4 months) vs. locally advanced (30.0 months) or metastatic (44.0 months, P = 0.041); and patients who received adjuvant therapy (87.4 months) compared with those who did not (30.0 months, P = 0.003), especially when receiving radiochemotherapy (106.7 months, P = 0.027). One patient (2.8%) had a complete response (CR) and nine patients (25.0%) achieved a partial response (PR) for an objective response rate of 27.8% with median response duration of 11 months (range: 4–93). Eighteen patients (50.0%) had disease stabilization for a disease control rate (DCR) of 77.8%. More patients receiving trabectedin in 1st-line of advanced disease achieved CR (16.7%) and PR (50.0%) than those in ≥ 2nd line/s (0.0% and 20.0%), whereas the DCR was similar across treatment lines. Reversible neutropenia was the most common grade 3/4 laboratory abnormality (19.4%). Conclusions: Trabectedin confers clinical benefit in patients with recurrent/metastatic uLMS, given after failure to an anthracycline-based regimen being comparable to those reported in clinical trials and with a manageable safety profile

First Results and Status of the LHC Test String 2

After the commissioning of String 2 Phase1 and the powering of the main circuits in autumn 2001, a short yet vigorous experimental program was carried-out to validate the final design choices for the technical systems of LHC. This program included the investigation of thermo-hydraulics of quenches quench propagation, power converter controls and tracking between power converters, as well as the measurement of currents induced in the beam screen after a quench and crossing the interconnects. Parameters significant for the LHC, such as heat loads, were also measured. During the winter shutdown the String was completed to a full cell with the addition of three pre-series dipoles (Phase 2). After a short description of the layout of Phase 1 and Phase 2, the results of the experiments are presented and the future experimental program is outlined